The first drug to reverse aging just entered human trials

In January 2026, the FDA quietly cleared something that had never existed before: a therapy designed to make old cells biologically younger. No supplement. No off-label hack. A gene therapy called ER-100, built on Harvard research that once restored vision in blind mice, is now being injected into human eyes.

The company behind it, Life Biosciences, was co-founded by Harvard geneticist David Sinclair. The therapy uses a stripped-down version of the Yamanaka factors, the four transcription factors that won Shinya Yamanaka the 2012 Nobel Prize for showing that adult cells can be reprogrammed back to a stem-cell-like state.

But here is the critical twist: ER-100 uses only three of those four factors. The fourth, c-Myc, is a known oncogene linked to cancer. By removing it and keeping just OCT4, SOX2, and KLF4, Sinclair's team discovered something remarkable: cells could be partially reprogrammed, restoring youthful epigenetic patterns without losing their identity or turning cancerous.

The mouse experiment that changed everything

In 2020, a study published in Nature landed on the journal's cover with the headline "Turning Back Time." Sinclair's team crushed the optic nerves of mice, injected a harmless virus carrying the three OSK genes into their eyes, and watched what happened.

The damaged retinal ganglion cells didn't just survive. They grew new axons back toward the brain. Mice with glaucoma-induced blindness regained measurable vision. The epigenetic clock of those cells, the chemical markers that accumulate as cells age, had been wound backward.

This was the first demonstration that epigenetic reprogramming could reverse age-related damage in a living mammal. Not slow it. Reverse it.

From mice to monkeys to humans

The leap from mice to humans required an intermediate step. Life Biosciences presented primate data at ARVO showing that a single intravitreal injection of ER-100 in monkeys with NAION-like optic nerve damage significantly restored pattern electroretinogram responses and improved healthy axon density compared to controls.

The primate results validated the mouse findings across species and cleared the path to a human trial. In January 2026, the FDA cleared the Investigational New Drug application for ER-100, and Life Biosciences initiated a Phase 1 clinical trial (NCT07290244) enrolling patients with open-angle glaucoma and non-arteritic anterior ischemic optic neuropathy.

Nature Biotechnology called it the first cellular rejuvenation therapy using partial epigenetic reprogramming to reach human trials.

Why this matters beyond the eyes

The eyes are just the entry point. Life Biosciences' Partial Epigenetic Reprogramming platform is designed to work across organ systems. The company's pipeline already includes ER-300, targeting liver disease, with preclinical data showing potential improvements in key metabolic dysfunction-associated steatohepatitis (MASH) scores.

The underlying theory, championed by Sinclair for over a decade, treats aging itself as an epigenetic disease. DNA doesn't degrade with age as much as the chemical instructions telling cells how to read that DNA become corrupted. Partial reprogramming proposes to restore those instructions without altering the genetic code itself.

If the Phase 1 trial confirms safety, the implications extend far beyond ophthalmology. Every organ system accumulates epigenetic damage. Every age-related disease, from neurodegeneration to cardiovascular decline, could theoretically benefit from the same three-factor approach.

For context on the same company's lifespan extension results, earlier preclinical work showed dramatic lifespan gains in mice. And if you're wondering how to measure your own biological age, organ-specific blood tests can now estimate which systems are aging fastest.

What this trial will and won't tell us

The Phase 1 study is a safety trial. It will measure tolerability, immune responses, and preliminary visual function changes, not whether ER-100 reverses systemic aging. The enrolled patients have specific optic neuropathies, not general age-related decline.

Results are expected within 12 to 18 months. If the therapy proves safe, Phase 2 efficacy trials could follow, potentially expanding to other organs.

Medical disclaimer: This article describes an investigational therapy in early clinical testing. ER-100 is not approved for any condition. Clinical outcomes in humans remain unknown. Consult a qualified healthcare provider before making medical decisions based on preclinical or Phase 1 data.

---

Related reading

• 109% longer lifespan in mice, and the FDA just approved the human trial
• A blood test now reveals which of your organs is aging fastest